Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 8/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.54 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.52 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290919 | 1.00 | BRAF (0.57) | BRAFKCNK3KCNK9KMT2AMEN1 | |
| SCHEMBL24010908 | 0.96 | BRAF (0.61) | BRAFKCNK3KCNK9KMT2AMEN1 | |
| SCHEMBL30290852 | 0.96 | BRAF (0.61) | BRAFKCNK3KCNK9KMT2AMEN1 | |
| SCHEMBL30290950 | 0.94 | KCNK3 (0.61) | BRAFKCNK3KCNK9DNMT1DNMT3A | |
| SCHEMBL24011296 | 0.94 | KCNK3 (0.61) | BRAFKCNK3KCNK9DNMT1DNMT3A | |
| SCHEMBL30290838 | 0.94 | KCNK3 (0.61) | BRAFKCNK3KCNK9DNMT1DNMT3A | |
| SCHEMBL24010261 | 0.94 | KCNK3 (0.61) | BRAFKCNK3KCNK9DNMT1DNMT3A | |
| SCHEMBL24003834 | 0.92 | KCNK3 (0.55) | BRAFKCNK3KCNK9KMT2AMEN1 | |
| SCHEMBL30232524 | 0.92 | KCNK3 (0.55) | BRAFKCNK3KCNK9KMT2AMEN1 | |
| SCHEMBL24003823 | 0.90 | BRAF (0.54) | BRAFKCNK3KCNK9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| CN-115996721-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | BRAF 154/4885KCNK3 2240/4885KCNK9 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.